DNAtrix Announces Oral Presentation of Positive Overall Survival Data With DNX-2401 in DIPG at the Society for Neuro-Oncology (SNO) Annual Meeting

UF startup DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, announced that data from the Phase 1 study of DNX-2401 in diffuse intrinsic pontine glioma (DIPG) was presented in an oral presentation at the 26th Annual Meeting and Education Day of the Society for Neuro-oncology (SNO), which was held from November 18-21, 2021 in Boston, MA.